应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
LQDA Liquidia Technologies Inc
休市中 11-13 16:00:00 EST
57.41
-0.71
-1.22%
盘后
56.92
-0.49
-0.85%
19:54 EST
最高
59.50
最低
57.00
成交量
193.31万
今开
58.37
昨收
58.12
日振幅
4.30%
总市值
51.73亿
流通市值
41.32亿
总股本
9,011万
成交额
1.12亿
换手率
2.69%
流通股本
7,197万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Liquidia Technologies Inc盘中上涨4.07%,财报后券商继续上调目标价
行情直击 · 11-12 23:42
异动解读|Liquidia Technologies Inc盘中上涨4.07%,财报后券商继续上调目标价
异动解读|Liquidia Technologies Inc盘中上涨5.91%,财报后获券商上调目标价
行情直击 · 11-11
异动解读|Liquidia Technologies Inc盘中上涨5.91%,财报后获券商上调目标价
异动解读|Liquidia Technologies Inc盘前上涨5.06%,财报后获券商上调目标价
行情直击 · 11-11
异动解读|Liquidia Technologies Inc盘前上涨5.06%,财报后获券商上调目标价
异动解读|Liquidia Technologies Inc盘前下跌10.17%,市场继续消化与美国联合医疗和解影响
行情直击 · 11-10
异动解读|Liquidia Technologies Inc盘前下跌10.17%,市场继续消化与美国联合医疗和解影响
异动解读|Liquidia Technologies Inc盘中上涨8.11%,与美国联合医疗达成和解协议
行情直击 · 11-10
异动解读|Liquidia Technologies Inc盘中上涨8.11%,与美国联合医疗达成和解协议
异动解读|Liquidia Technologies Inc盘中上涨9.6%,报46.82美元
行情直击 · 11-04
异动解读|Liquidia Technologies Inc盘中上涨9.6%,报46.82美元
美股异动 | 与美国联合医疗达成和解协议 Liquidia(LQDA.US)早盘大涨超25%
智通财经 · 10-14
美股异动 | 与美国联合医疗达成和解协议 Liquidia(LQDA.US)早盘大涨超25%
美股异动|Liquidia股价飙升40%,创2023年12月以来最大盘中涨幅
老虎快讯 · 10-14
美股异动|Liquidia股价飙升40%,创2023年12月以来最大盘中涨幅
异动解读|Liquidia Technologies Inc盘中上涨34.22%,减持扰动消化后资金重估产品进展
行情直击 · 10-14
异动解读|Liquidia Technologies Inc盘中上涨34.22%,减持扰动消化后资金重估产品进展
异动解读|Liquidia Technologies Inc盘前上涨48.45%,减持扰动消化后资金重估产品进展
行情直击 · 10-14
异动解读|Liquidia Technologies Inc盘前上涨48.45%,减持扰动消化后资金重估产品进展
异动解读|Liquidia Technologies Inc夜盘上涨41.29%,减持扰动消化后资金重估产品进展
行情直击 · 10-14
异动解读|Liquidia Technologies Inc夜盘上涨41.29%,减持扰动消化后资金重估产品进展
异动解读|Liquidia Technologies Inc盘后上涨31.63%,董事长减持利空后资金回补
行情直击 · 10-14
异动解读|Liquidia Technologies Inc盘后上涨31.63%,董事长减持利空后资金回补
异动解读|Liquidia盘中上涨9.67%,FDA快速通道资格与商业化放量提振信心
行情直击 · 10-12
异动解读|Liquidia盘中上涨9.67%,FDA快速通道资格与商业化放量提振信心
异动解读|Liquidia盘中上涨9.07%,Yutrepia再获FDA快速通道资格提振市场信心
行情直击 · 10-08
异动解读|Liquidia盘中上涨9.07%,Yutrepia再获FDA快速通道资格提振市场信心
异动解读|Liquidia Technologies盘中下跌45.41%,专利诉讼败诉重创市场信心
行情直击 · 10-01
异动解读|Liquidia Technologies盘中下跌45.41%,专利诉讼败诉重创市场信心
Liquidia公司Re-Warm研究预计2026年10月启动,主要阶段将于2027年2月收官
美股速递 · 09-03
Liquidia公司Re-Warm研究预计2026年10月启动,主要阶段将于2027年2月收官
异动解读|Liquidia Technologies盘中下跌5.1%,Q2每股收益不及预期延续获利回吐
行情直击 · 08-18
异动解读|Liquidia Technologies盘中下跌5.1%,Q2每股收益不及预期延续获利回吐
异动解读|Liquidia Technologies盘中上涨5.18%,Q2营收大幅超预期下连跌后反弹
行情直击 · 08-14
异动解读|Liquidia Technologies盘中上涨5.18%,Q2营收大幅超预期下连跌后反弹
异动解读|Liquidia Technologies盘中下跌5.06%,Q2每股收益不及预期延续获利回吐压力
行情直击 · 08-14
异动解读|Liquidia Technologies盘中下跌5.06%,Q2每股收益不及预期延续获利回吐压力
异动解读 | Liquidia Technologies盘中大跌5.81%,Q2每股收益不及预期引发获利回吐
异动解读 · 08-13
异动解读 | Liquidia Technologies盘中大跌5.81%,Q2每股收益不及预期引发获利回吐
加载更多
公司概况
公司名称:
Liquidia Technologies Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Liquidia Corporation于2020年6月17日在特拉华州成立。该公司是一家生物制药公司,专注于解决未满足患者需求产品的开发、制造和商业化,目前的重点是肺动脉高压的治疗。该公司通过两家全资子公司Liquidia Technologies和Liquidia PAH作为单一实体运营。该公司通过应用心肺疾病方面的专业知识和专有的PRINT技术进行新产品的研究、开发和制造,PRINT技术是一种粒子工程平台,能够精确生产均匀的药物颗粒,旨在提高广泛疗法的安全性、有效性和性能。通过与第三方的产品开发和研究,该公司拥有将PRINT应用于多种给药途径和药物有效载荷的经验,包括吸入疗法、疫苗、生物制剂、核酸和眼科植入物等。
发行价格:
--
{"stockData":{"symbol":"LQDA","market":"US","secType":"STK","nameCN":"Liquidia Technologies Inc","latestPrice":57.41,"timestamp":1794603600000,"preClose":58.12,"halted":0,"volume":1933075,"hourTrading":{"tag":"盘后","latestPrice":56.9225,"preClose":57.41,"latestTime":"19:54 EST","volume":204449,"amount":11735415.1406,"timestamp":1794617694579,"change":-0.4875,"changeRate":-0.008492,"amplitude":0.024909},"delay":0,"changeRate":-0.012216104611149362,"floatShares":71973928,"shares":90106442,"eps":-1.065589,"marketStatus":"休市中","change":-0.71,"latestTime":"11-13 16:00:00 EST","open":58.37,"high":59.5,"low":57,"amount":112104729.55355,"amplitude":0.043014,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.065589,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1532577600000,"exchange":"NASDAQ","adjPreClose":58.12,"preHourTrading":{"tag":"盘前","latestPrice":58.9997,"preClose":58.12,"latestTime":"09:29 EST","volume":1382,"amount":80243.334108,"timestamp":1794580180650,"change":0.8797,"changeRate":0.015136,"amplitude":0.021846},"postHourTrading":{"tag":"盘后","latestPrice":56.9225,"preClose":57.41,"latestTime":"19:54 EST","volume":204449,"amount":11735415.1406,"timestamp":1794617694579,"change":-0.4875,"changeRate":-0.008492,"amplitude":0.024909},"volumeRatio":0.7254602422392757,"impliedVol":0.6907,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/LQDA","defaultTab":"news","newsList":[{"id":"1145401978","title":"异动解读|Liquidia Technologies Inc盘中上涨4.07%,财报后券商继续上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1145401978","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145401978?lang=zh_cn&edition=full","pubTime":"2026-11-12 23:42","pubTimestamp":1794498175,"startTime":"0","endTime":"0","summary":"11月12日,Liquidia Technologies Inc盘中上涨4.07%,报57.45美元/股,成交额2496.77万美元。消息面上,公司三季度业绩披露后,市场继续交易券商上调目标价与收入预期的逻辑,推动股价延续强势。公司三季度营收2.253亿美元,高于市场预期的2.142亿美元,其中YUTREPIA净销售额2.227亿美元,环比增长31%,10月患者发货量创单月新高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia财报后上涨,券商纷纷上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198752765","title":"异动解读|Liquidia Technologies Inc盘中上涨5.91%,财报后获券商上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1198752765","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198752765?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:56","pubTimestamp":1794408987,"startTime":"0","endTime":"0","summary":"11月11日,Liquidia Technologies Inc盘中上涨5.91%,报54.35美元/股,成交额2233.37万美元。消息面上,公司披露三季度业绩后,多家机构上调目标价,带动市场情绪继续回暖。BofA将目标价上调至54美元,Needham上调至66美元,BTIG重申买入并给出87美元目标价。尽管受约3.897亿美元诉讼和解费用影响,公司单季每股亏损2.64美元,但市场更关注核心产品商业化推进及和解后不确定性下降。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia盘中上涨,财报后获多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140587824","title":"异动解读|Liquidia Technologies Inc盘前上涨5.06%,财报后获券商上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1140587824","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140587824?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:28","pubTimestamp":1794407329,"startTime":"0","endTime":"0","summary":"11月11日,Liquidia Technologies Inc盘前上涨5.06%,报54.07美元/股,成交额133.05万美元。消息面上,公司披露三季度业绩后,多家机构上调目标价,其中BofA将目标价从42美元上调至54美元,Needham将目标价从58美元上调至66美元,BTIG重申买入评级并给出87美元目标价。尽管公司因3.897亿美元诉讼和解费用拖累,单季每股亏损2.64美元,但市场更关注核心产品商业化推进及和解后经营不确定性下降。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia盘前上涨,获多家券商上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177553410","title":"异动解读|Liquidia Technologies Inc盘前下跌10.17%,市场继续消化与美国联合医疗和解影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1177553410","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177553410?lang=zh_cn&edition=full","pubTime":"2026-11-10 19:31","pubTimestamp":1794310267,"startTime":"0","endTime":"0","summary":"11月10日,Liquidia Technologies Inc盘前下跌10.17%,报45.0美元/股,成交额15.84万美元。消息面上,市场仍在消化公司与美国联合医疗达成和解协议的最新影响。公开信息显示,Liquidia同意支付3.807亿美元,并停止对曲前列尼尔注射剂的商业支持;该事项此前曾推动股价大涨,并带动投行将评级上调至买入、目标价70美元。公司最新一季营收为1.717亿美元,YUTREPIA单季净销售额约1.704亿美元,核心产品商业化进展仍是市场关注重点。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Liquidia Technologies盘前下跌,和解影响仍在发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148906340","title":"异动解读|Liquidia Technologies Inc盘中上涨8.11%,与美国联合医疗达成和解协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1148906340","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148906340?lang=zh_cn&edition=full","pubTime":"2026-11-10 00:37","pubTimestamp":1794242234,"startTime":"0","endTime":"0","summary":"11月10日,Liquidia Technologies Inc盘中上涨8.11%,报47.935美元/股,成交额3912.98万美元。消息面上,市场近期关注公司与美国联合医疗达成和解协议,该事项曾推动其股价单日大涨,并带来投行态度转暖。此外,BTIG随后将公司评级上调至买入,目标价70美元;公司上一季度实现营收1.717亿美元,YUTREPIA单季净销售额约1.704亿美元,显示核心产品商业化进展仍是市场关注重点。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia盘中大涨,与美国联合医疗和解","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139143099","title":"异动解读|Liquidia Technologies Inc盘中上涨9.6%,报46.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139143099","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139143099?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:16","pubTimestamp":1793805414,"startTime":"0","endTime":"0","summary":"11月4日,Liquidia Technologies Inc盘中上涨9.6%,报46.82美元/股,成交额8896.27万美元。Liquidia Technologies Inc所在的制药行业中,礼来上涨0.54%,诺和诺德上涨6.02%,强生上涨0.94%,辉瑞上涨0.48%,阿斯利康上涨2.17%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675325537","title":"美股异动 | 与美国联合医疗达成和解协议 Liquidia(LQDA.US)早盘大涨超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675325537","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675325537?lang=zh_cn&edition=full","pubTime":"2026-10-14 23:34","pubTimestamp":1791992087,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4007","BK4139","LQDA","LU1571399168.USD","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125870583","title":"美股异动|Liquidia股价飙升40%,创2023年12月以来最大盘中涨幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1125870583","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125870583?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:36","pubTimestamp":1791985010,"startTime":"0","endTime":"0","summary":"美国生物制药公司Liquidia股价飙升40%,创2023年12月以来最大盘中涨幅。","market":"sg","thumbnail":"https://static.tigerbbs.com/edc98c04cdc47dd0d16e08274ce9a364","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/edc98c04cdc47dd0d16e08274ce9a364"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172077158","title":"异动解读|Liquidia Technologies Inc盘中上涨34.22%,减持扰动消化后资金重估产品进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1172077158","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172077158?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:31","pubTimestamp":1791984668,"startTime":"0","endTime":"0","summary":"10月14日,Liquidia Technologies Inc盘中上涨34.22%,报36.0美元/股,成交额1.38亿美元。消息面上,前期董事长经由Canaan LP减持带来的负面情绪有所钝化,资金重新聚焦Yutrepia适应症拓展与商业化放量。已披露信息显示,Stephen Bloch于10月5日以每股27.13美元出售235477股,套现约640万美元,相关主体持股降至零;但公司基本面方面,Yutrepia已获FDA快速通道资格,用于系统性硬化症相关雷诺现象,且二季度YUTREPIA净销售额约1.704亿美元,环比增长31%,反映市场更关注后续增长兑现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia异动拉升,资金重估产品进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153857400","title":"异动解读|Liquidia Technologies Inc盘前上涨48.45%,减持扰动消化后资金重估产品进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1153857400","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153857400?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:02","pubTimestamp":1791964973,"startTime":"0","endTime":"0","summary":"10月14日,Liquidia Technologies Inc盘前上涨48.45%,报38.98美元/股,成交额40.93万美元。消息面上,前期董事长经由Canaan LP减持带来的负面情绪有所钝化,资金重新聚焦Yutrepia适应症拓展与商业化放量。已披露信息显示,董事长Stephen Bloch于10月5日以每股27.13美元出售235477股,套现约640万美元,相关主体持股降至零;但公司基本面方面,Yutrepia已获FDA快速通道资格,用于系统性硬化症相关雷诺现象,且二季度YUTREPIA净销售额约1.704亿美元,环比增长31%,反映市场更关注后续增长兑现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减持扰动消化,Liquidia盘前大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100103077","title":"异动解读|Liquidia Technologies Inc夜盘上涨41.29%,减持扰动消化后资金重估产品进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100103077","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100103077?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:02","pubTimestamp":1791936166,"startTime":"0","endTime":"0","summary":"10月14日,Liquidia Technologies Inc夜盘上涨41.29%,报37.88美元/股,成交额1.25万美元。消息面上,市场对董事长经由Canaan LP减持的利空反应有所钝化,资金重新聚焦Yutrepia适应症拓展与商业化放量。此前公司董事长Stephen Bloch于10月5日以每股27.13美元出售235477股,套现约640万美元,相关主体持股降至零;但公司基本面方面,Yutrepia已获FDA快速通道资格,用于系统性硬化症相关雷诺现象,且二季度YUTREPIA净销售额约1.704亿美元,环比增长31%,显示市场更关注后续增长兑现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减持扰动消化,Liquidia夜盘大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104097553","title":"异动解读|Liquidia Technologies Inc盘后上涨31.63%,董事长减持利空后资金回补","url":"https://stock-news.laohu8.com/highlight/detail?id=1104097553","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104097553?lang=zh_cn&edition=full","pubTime":"2026-10-14 05:46","pubTimestamp":1791928017,"startTime":"0","endTime":"0","summary":"10月14日,Liquidia Technologies Inc盘后上涨31.63%,报35.0447美元/股,成交额533.95万美元。最新可见消息面显示,公司此前被列为一周负面股票关注对象,因董事长Stephen Bloch于10月5日经由Canaan LP以每股27.13美元出售235477股,套现约640万美元;该笔交易后Canaan LP持股降至零。Yutrepia此前获FDA快速通道资格,用于系统性硬化症相关雷诺现象,且公司二季度YUTREPIA净销售额约1.704亿美元,环比增长31%。在前期减持消息扰动后,股价盘后大幅反弹,显示市场更关注产品拓展与商业化进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"董事长减持利空落地,Liquidia盘后强势反弹","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190617819","title":"异动解读|Liquidia盘中上涨9.67%,FDA快速通道资格与商业化放量提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1190617819","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190617819?lang=zh_cn&edition=full","pubTime":"2026-10-12 21:31","pubTimestamp":1791811914,"startTime":"0","endTime":"0","summary":"10月12日,Liquidia盘中上涨9.67%,报29.4401美元/股,成交额550.62万美元。消息面上,FDA授予Yutrepia吸入粉末快速通道资格,用于治疗系统性硬化症相关的雷诺现象,拓展了公司在肺动脉高压之外的适应症布局,并有望获得优先审评及更密切的监管沟通。Liquidia Corporation是一家生物制药公司,专注于开发、制造和商业化满足未满足患者需求的产品,目前主要聚焦肺动脉高压治疗,拥有专有的PRINT粒子工程平台。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia获FDA快速通道,商业化放量提振信心","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120583044","title":"异动解读|Liquidia盘中上涨9.07%,Yutrepia再获FDA快速通道资格提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1120583044","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120583044?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:17","pubTimestamp":1791469023,"startTime":"0","endTime":"0","summary":"10月8日,Liquidia盘中上涨9.07%,报29.1美元/股,成交额3217.11万美元。消息面上,美国FDA授予Yutrepia吸入粉末快速通道资格,用于治疗系统性硬化症相关的雷诺现象,为公司在肺动脉高压之外的适应症拓展提供重要催化。快速通道资格旨在加速严重疾病疗法的开发与审评,有助于Liquidia与FDA更频繁沟通,并可能获得优先审评资格。此外,Yutrepia在第二季度实现净产品销售额约1.704亿美元,环比增长31%,商业化放量延续强劲趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia获FDA快速通道资格,股价强势上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100610899","title":"异动解读|Liquidia Technologies盘中下跌45.41%,专利诉讼败诉重创市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1100610899","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100610899?lang=zh_cn&edition=full","pubTime":"2026-10-01 02:11","pubTimestamp":1790791872,"startTime":"0","endTime":"0","summary":"10月1日,Liquidia Technologies盘中下跌45.41%,报38.69美元/股,成交额3.97亿美元。该裁决意味着Liquidia核心产品YUTREPIA可能面临专利侵权赔偿或上市限制风险,对公司商业化前景构成重大不确定性。此次专利败诉判决直接冲击了市场对其持续放量增长的预期。Liquidia Corporation是一家生物制药公司,专注于肺动脉高压治疗领域,依托专有PRINT粒子工程技术平台进行药物研发与制造。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"专利败诉重创信心,股价盘中跳水","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192786112","title":"Liquidia公司Re-Warm研究预计2026年10月启动,主要阶段将于2027年2月收官","url":"https://stock-news.laohu8.com/highlight/detail?id=1192786112","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192786112?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:31","pubTimestamp":1788435071,"startTime":"0","endTime":"0","summary":"Liquidia公司宣布,其Re-Warm研究项目计划于2026年10月正式启动。该研究的主要阶段预计在2027年2月完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184500619","title":"异动解读|Liquidia Technologies盘中下跌5.1%,Q2每股收益不及预期延续获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1184500619","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184500619?lang=zh_cn&edition=full","pubTime":"2026-08-18 23:03","pubTimestamp":1787065409,"startTime":"0","endTime":"0","summary":"8月18日,Liquidia Technologies盘中下跌5.1%,报73.74美元/股,成交额1996.73万美元,延续财报发布后的回调走势。消息面上,公司于8月12日发布Q2财报,每股收益0.74美元,低于FactSet预期的0.76美元;营收1.717亿美元,同比大幅增长,超出市场预期的1.685亿美元。核心产品YUTREPIA净销售额约1.704亿美元,环比增长31%,独立患者处方数约5,900人。尽管营收端持续放量,但EPS未达部分机构预期,叠加公司股价年内涨幅已超一倍,市场获利回吐情绪持续释放。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197326088","title":"异动解读|Liquidia Technologies盘中上涨5.18%,Q2营收大幅超预期下连跌后反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1197326088","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197326088?lang=zh_cn&edition=full","pubTime":"2026-08-14 23:03","pubTimestamp":1786719801,"startTime":"0","endTime":"0","summary":"8月14日,Liquidia Technologies盘中上涨5.18%,报75.84美元/股,成交额5809.96万美元。消息面上,公司于8月12日发布Q2财报,营收1.717亿美元同比增长约18.5倍,核心产品YUTREPIA净销售额约1.704亿美元,环比增长31%,独立患者处方数约5,900人,营收超出市场预期的1.685亿美元;但每股收益0.74美元略低于FactSet预期的0.76美元。此前因EPS未达预期叠加年内涨幅已超一倍,股价在前两个交易日累计回调超10%。美银证券此前将公司评级下调至\"中性\",目标价79美元,当前股价仍低于该目标价水平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193199356","title":"异动解读|Liquidia Technologies盘中下跌5.06%,Q2每股收益不及预期延续获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193199356","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193199356?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:14","pubTimestamp":1786641293,"startTime":"0","endTime":"0","summary":"8月14日,Liquidia Technologies盘中下跌5.06%,报74.8美元/股,成交额1.46亿美元,延续前一交易日跌势。消息面上,公司于8月12日盘前发布第二季度财报,Q2每股收益为0.74美元,低于FactSet预期的0.76美元;营收1.717亿美元,同比增长约18.5倍,核心产品YUTREPIA净销售额约1.704亿美元,环比增长31%,独立患者处方数约5,900人,营收超出市场一致预期的1.685亿美元。尽管营收端表现亮眼,但EPS未达部分机构预期,叠加此前公司股价年内涨幅已超一倍,市场获利回吐情绪浓厚。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146449266","title":"异动解读 | Liquidia Technologies盘中大跌5.81%,Q2每股收益不及预期引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1146449266","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146449266?lang=zh_cn&edition=full","pubTime":"2026-08-13 00:40","pubTimestamp":1786552857,"startTime":"0","endTime":"0","summary":"Liquidia Technologies Inc(LQDA)今日盘中大幅下挫5.81%,引发市场广泛关注。消息面上,公司于盘前发布第二季度财报。尽管营收同比增长约18.5倍至17.17亿美元,核心产品YUTREPIA净销售额达17.04亿美元,均超出市场预期,但每股收益为0.74美元,低于FactSet预期的0.76美元及LSEG汇总的0.7722美元预期。净利润亦未达部分分析师预测。此前公司股价年内涨幅已超过一倍,市场已充分消化高增长预期。在EPS不及预期的情况下,投资者选择获利了结。此外,美银证券此前已将公司评级从“买入”下调至“中性”,目标价定为79美元,这对市场情绪形成进一步压制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LQDA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.liquidia.com","stockEarnings":[{"period":"1week","weight":0.293},{"period":"1month","weight":0.6915},{"period":"3month","weight":-0.2288},{"period":"6month","weight":0.0084},{"period":"1year","weight":1.131},{"period":"ytd","weight":0.6645}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Liquidia Corporation于2020年6月17日在特拉华州成立。该公司是一家生物制药公司,专注于解决未满足患者需求产品的开发、制造和商业化,目前的重点是肺动脉高压的治疗。该公司通过两家全资子公司Liquidia Technologies和Liquidia PAH作为单一实体运营。该公司通过应用心肺疾病方面的专业知识和专有的PRINT技术进行新产品的研究、开发和制造,PRINT技术是一种粒子工程平台,能够精确生产均匀的药物颗粒,旨在提高广泛疗法的安全性、有效性和性能。通过与第三方的产品开发和研究,该公司拥有将PRINT应用于多种给药途径和药物有效载荷的经验,包括吸入疗法、疫苗、生物制剂、核酸和眼科植入物等。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.081499},{"month":2,"riseRate":0.75,"avgChangeRate":0.042796},{"month":3,"riseRate":0.5,"avgChangeRate":-0.012167},{"month":4,"riseRate":0.375,"avgChangeRate":-0.058158},{"month":5,"riseRate":0.875,"avgChangeRate":0.19539},{"month":6,"riseRate":0.25,"avgChangeRate":-0.029487},{"month":7,"riseRate":0.375,"avgChangeRate":0.004032},{"month":8,"riseRate":0.444444,"avgChangeRate":0.021851},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.017529},{"month":10,"riseRate":0.666667,"avgChangeRate":0.077362},{"month":11,"riseRate":0.777778,"avgChangeRate":0.097034},{"month":12,"riseRate":0.75,"avgChangeRate":0.150821}],"exchange":"NASDAQ","name":"Liquidia Technologies Inc","nameEN":"Liquidia Technologies Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Liquidia Technologies Inc(LQDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Liquidia Technologies Inc(LQDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Liquidia Technologies Inc,LQDA,Liquidia Technologies Inc股票,Liquidia Technologies Inc股票老虎,Liquidia Technologies Inc股票老虎国际,Liquidia Technologies Inc行情,Liquidia Technologies Inc股票行情,Liquidia Technologies Inc股价,Liquidia Technologies Inc股市,Liquidia Technologies Inc股票价格,Liquidia Technologies Inc股票交易,Liquidia Technologies Inc股票购买,Liquidia Technologies Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Liquidia Technologies Inc(LQDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Liquidia Technologies Inc(LQDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}